QNCX

Quince Therapeutics, Inc. (QNCX) - 10-Q Summary for Q1 2026

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended March 31, 2026. Quince Therapeutics, Inc. is a late-stage biotechnology company focused on its proprietary AIDE technology platform. The quarter was defined by the completion of the pivotal Phase 3 NEAT clinical trial for its lead asset, eDSP, which failed to meet primary and secondary endpoints for the treatment of Ataxia-Telangiectasia (A-T). Consequently, the Company ceased development of eDSP and engaged a financial advisor to evaluate strategic alternatives, including a potential reverse merger. The Company reported a substantial doubt regarding its ability to continue as a going concern within one year of the filing date due to insufficient cash resources to fund operations without additional financing.

Key Financial Metrics

Note: Net income for Q1 2026 is non-cash driven, primarily due to fair value adjustments on financial liabilities and an impairment charge.

Material Changes vs. Prior Period

• Clinical Trial Failure: The Phase 3 NEAT trial for eDSP did not reach statistical significance. This triggered a $67.8 million non-cash impairment charge on intangible assets (IPR&D and trade name) and the elimination of $64.3 million in contingent consideration liabilities related to the EryDel acquisition.
• Debt Settlement: The Company settled its European Investment Bank (EIB) loan in full with a payment of approximately $5.5 million in March 2026, resulting in a $12.2 million gain from the fair value adjustment of the debt.
• Warrant Liability Adjustment: A $31.1 million gain was recorded due to the fair value adjustment of warrant liabilities, driven by changes in the Company's stock price and volatility.
• Reverse Stock Split: A 1-for-10 reverse stock split was effected on April 10, 2026. All share and per-share data in this report have been retroactively adjusted.
• Capital Raise: The Company raised approximately $15.0 million through its At-The-Market (ATM) program during the quarter.

Outlook, Risks, and Management Commentary

• Strategic Alternatives: Management is focused on preserving cash and evaluating strategic alternatives, including a reverse merger, to maximize shareholder value. No agreements are currently in place.
• Liquidity Risk: With $18.2 million in cash as of March 31, 2026, and no revenue-generating products, the Company does not believe it has sufficient resources to fund operations for the next 12 months. Additional equity or debt financing is required.
• Nasdaq Compliance: The Company received notices from Nasdaq regarding non-compliance with the minimum market value of listed securities requirement ($50 million). While it regained compliance with the minimum bid price, it has until September 14, 2026, to regain full compliance or face delisting.
• Going Concern: The financial statements are prepared on a going concern basis, but substantial doubt exists regarding the Company's ability to continue operations without further funding or a successful strategic transaction.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $18.2 million cash balance against current burn rates and the timeline for securing additional funding.
• Strategic Transaction Progress: Monitor updates on the engagement with LifeSci Capital and any potential reverse merger or asset sale agreements.
• Nasdaq Listing Status: Track the Company's progress in meeting the $50 million market value requirement to avoid delisting.
• ATM Program Utilization: Review subsequent filings for further dilution from the ATM program, which had $53.1 million remaining available as of March 31, 2026.
• Non-Cash Income Quality: Understand that the reported net income is largely comprised of non-cash accounting adjustments (warrant/debt fair value changes) rather than operational profitability.